SMA News for HCPs: Stasimon, nusinersen in adult patients, managing collapsing spine deformity & more

SMA News for HCPs: Stasimon, nusinersen in adult patients, managing collapsing spine deformity & more

Understanding SMA Stasimon contributes to the loss of sensory synapses and motor neuron death in a mouse model of spinal muscular atrophy.1 In this paper, the authors elucidate a mechanism of the motor neuron degeneration that occurs in SMA. Specifically, the authors...
FDA Approves AveXis’ Gene Therapy Zolgensma to Treat SMA in Children Up to Age 2

FDA Approves AveXis’ Gene Therapy Zolgensma to Treat SMA in Children Up to Age 2

Zolgensma, a first gene therapy for spinal muscular atrophy — and first for any chronic neurologic disease — is now an approved and potential “one-time” intravenous treatment for pre-symptomatic newborns through 2-year-olds with any type of SMA, the U.S. Food and Drug...
SMA Care Has Significant Financial, Career, Social, and Psychological Impact on Families, Study Reports

SMA Care Has Significant Financial, Career, Social, and Psychological Impact on Families, Study Reports

Taking care of a child with spinal muscular atrophy (SMA) significantly affects several aspects of  families’ lives, including finances, career choices, social life, and mental health, according to an Australian study. The study, “Financial, opportunity and...